Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 119 entries
Sorted by: Best Match Show Resources per page
Long noncoding RNAs in cancer: from function to translation.

Trends in cancer

Sahu A, Singhal U, Chinnaiyan AM.
PMID: 26693181
Trends Cancer. 2015 Oct 01;1(2):93-109. doi: 10.1016/j.trecan.2015.08.010.

While our understanding of the molecular mechanisms underlying cancer has significantly improved, most of our knowledge focuses on protein-coding genes that make up a fraction of the genome. Recent studies have uncovered thousands of long noncoding RNAs (lncRNAs) that...

Cite
Sahu A, Singhal U, Chinnaiyan AM. Long noncoding RNAs in cancer: from function to translation. Trends Cancer. 2015;1(2):93-109doi: 10.1016/j.trecan.2015.08.010.
Sahu, A., Singhal, U., & Chinnaiyan, A. M. (2015). Long noncoding RNAs in cancer: from function to translation. Trends in cancer, 1(2), 93-109. https://doi.org/10.1016/j.trecan.2015.08.010
Sahu, Anirban, et al. "Long noncoding RNAs in cancer: from function to translation." Trends in cancer vol. 1,2 (2015): 93-109. doi: https://doi.org/10.1016/j.trecan.2015.08.010
Sahu A, Singhal U, Chinnaiyan AM. Long noncoding RNAs in cancer: from function to translation. Trends Cancer. 2015 Oct 01;1(2):93-109. doi: 10.1016/j.trecan.2015.08.010. PMID: 26693181; PMCID: PMC4672369.
Copy Download .nbib Format: NLM
ONCOMINE: a cancer microarray database and integrated data-mining platform.

Neoplasia (New York, N.Y.)

Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM.
PMID: 15068665
Neoplasia. 2004 Jan-Feb;6(1):1-6. doi: 10.1016/s1476-5586(04)80047-2.

DNA microarray technology has led to an explosion of oncogenomic analyses, generating a wealth of data and uncovering the complex gene expression patterns of cancer. Unfortunately, due to the lack of a unifying bioinformatic resource, the majority of these...

Cite
Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1-6doi: 10.1016/s1476-5586(04)80047-2.
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pandey, A., & Chinnaiyan, A. M. (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (New York, N.Y.), 6(1), 1-6. https://doi.org/10.1016/s1476-5586(04)80047-2
Rhodes, Daniel R, et al. "ONCOMINE: a cancer microarray database and integrated data-mining platform." Neoplasia (New York, N.Y.) vol. 6,1 (2004): 1-6. doi: https://doi.org/10.1016/s1476-5586(04)80047-2
Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004 Jan-Feb;6(1):1-6. doi: 10.1016/s1476-5586(04)80047-2. PMID: 15068665; PMCID: PMC1635162.
Copy Download .nbib Format: NLM
Pathway analysis reveals functional convergence of gene expression profiles in breast cancer.

BMC medical genomics

Shen R, Chinnaiyan AM, Ghosh D.
PMID: 18588682
BMC Med Genomics. 2008 Jun 27;1:28. doi: 10.1186/1755-8794-1-28.

BACKGROUND: A recent study has shown high concordance of several breast-cancer gene signatures in predicting disease recurrence despite minimal overlap of the gene lists. It raises the question if there are common themes underlying such prediction concordance that are...

Cite
Shen R, Chinnaiyan AM, Ghosh D. Pathway analysis reveals functional convergence of gene expression profiles in breast cancer. BMC Med Genomics. 2008;1:28doi: 10.1186/1755-8794-1-28.
Shen, R., Chinnaiyan, A. M., & Ghosh, D. (2008). Pathway analysis reveals functional convergence of gene expression profiles in breast cancer. BMC medical genomics, 128. https://doi.org/10.1186/1755-8794-1-28
Shen, Ronglai, et al. "Pathway analysis reveals functional convergence of gene expression profiles in breast cancer." BMC medical genomics vol. 1 (2008): 28. doi: https://doi.org/10.1186/1755-8794-1-28
Shen R, Chinnaiyan AM, Ghosh D. Pathway analysis reveals functional convergence of gene expression profiles in breast cancer. BMC Med Genomics. 2008 Jun 27;1:28. doi: 10.1186/1755-8794-1-28. PMID: 18588682; PMCID: PMC2447843.
Copy Download .nbib Format: NLM
Hazards of contrast-induced acute kidney injury in elderly women.

Women's health (London, England)

McCullough PA, Chinnaiyan KM.
PMID: 19245350
Womens Health (Lond). 2009 Mar;5(2):123-5. doi: 10.2217/17455057.5.2.123.

No abstract available.

Cite
McCullough PA, Chinnaiyan KM. Hazards of contrast-induced acute kidney injury in elderly women. Womens Health (Lond). 2009;5(2):123-5doi: 10.2217/17455057.5.2.123.
McCullough, P. A., & Chinnaiyan, K. M. (2009). Hazards of contrast-induced acute kidney injury in elderly women. Women's health (London, England), 5(2), 123-5. https://doi.org/10.2217/17455057.5.2.123
McCullough, Peter A, and Chinnaiyan, Kavitha M. "Hazards of contrast-induced acute kidney injury in elderly women." Women's health (London, England) vol. 5,2 (2009): 123-5. doi: https://doi.org/10.2217/17455057.5.2.123
McCullough PA, Chinnaiyan KM. Hazards of contrast-induced acute kidney injury in elderly women. Womens Health (Lond). 2009 Mar;5(2):123-5. doi: 10.2217/17455057.5.2.123. PMID: 19245350.
Copy Download .nbib Format: NLM
Subclinical coronary atherosclerosis identified by coronary computed tomographic angiography in asymptomatic morbidly obese patients.

Heart international

Lubanski MS, Vanhecke TE, Chinnaiyan KM, Franklin BA, McCullough PA.
PMID: 21977300
Heart Int. 2010 Dec 31;5(2):e15. doi: 10.4081/hi.2010.e15.

Obesity is a common public health problem and obese individuals in particular have a disproportionate incidence of acute coronary events. This study was undertaken to identify coronary artery lesions as well as associated clinical features, risk factors and demographics...

Cite
Lubanski MS, Vanhecke TE, Chinnaiyan KM, et al. Subclinical coronary atherosclerosis identified by coronary computed tomographic angiography in asymptomatic morbidly obese patients. Heart Int. 2010;5(2):e15doi: 10.4081/hi.2010.e15.
Lubanski, M. S., Vanhecke, T. E., Chinnaiyan, K. M., Franklin, B. A., & McCullough, P. A. (2010). Subclinical coronary atherosclerosis identified by coronary computed tomographic angiography in asymptomatic morbidly obese patients. Heart international, 5(2), e15. https://doi.org/10.4081/hi.2010.e15
Lubanski, Martin S, et al. "Subclinical coronary atherosclerosis identified by coronary computed tomographic angiography in asymptomatic morbidly obese patients." Heart international vol. 5,2 (2010): e15. doi: https://doi.org/10.4081/hi.2010.e15
Lubanski MS, Vanhecke TE, Chinnaiyan KM, Franklin BA, McCullough PA. Subclinical coronary atherosclerosis identified by coronary computed tomographic angiography in asymptomatic morbidly obese patients. Heart Int. 2010 Dec 31;5(2):e15. doi: 10.4081/hi.2010.e15. PMID: 21977300; PMCID: PMC3184688.
Copy Download .nbib Format: NLM
Metformin Use Is Not Associated With B.

Frontiers in endocrinology

Elhadd T, Ponirakis G, Dabbous Z, Siddique M, Chinnaiyan S, Malik RA.
PMID: 29887831
Front Endocrinol (Lausanne). 2018 May 25;9:248. doi: 10.3389/fendo.2018.00248. eCollection 2018.

BACKGROUND: Metformin may lead to BAIMS: Determine whether Metformin intake is associated with BMETHODS: Patients with type 2 diabetes mellitus (T2DM) (RESULTS: Comparing Metformin to non-Metformin users there were no differences in BCONCLUSION: Serum B

Cite
Elhadd T, Ponirakis G, Dabbous Z, et al. Metformin Use Is Not Associated With B. Front Endocrinol (Lausanne). 2018;9:248doi: 10.3389/fendo.2018.00248.
Elhadd, T., Ponirakis, G., Dabbous, Z., Siddique, M., Chinnaiyan, S., & Malik, R. A. (2018). Metformin Use Is Not Associated With B. Frontiers in endocrinology, 9248. https://doi.org/10.3389/fendo.2018.00248
Elhadd, Tarik, et al. "Metformin Use Is Not Associated With B." Frontiers in endocrinology vol. 9 (2018): 248. doi: https://doi.org/10.3389/fendo.2018.00248
Elhadd T, Ponirakis G, Dabbous Z, Siddique M, Chinnaiyan S, Malik RA. Metformin Use Is Not Associated With B. Front Endocrinol (Lausanne). 2018 May 25;9:248. doi: 10.3389/fendo.2018.00248. eCollection 2018. PMID: 29887831; PMCID: PMC5980977.
Copy Download .nbib Format: NLM
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.

The Journal of clinical investigation

Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W.
PMID: 29608143
J Clin Invest. 2018 Apr 02;128(4):1708. doi: 10.1172/JCI120803. Epub 2018 Apr 02.

No abstract available.

Cite
Lin H, Wei S, Hurt EM, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest. 2018;128(4):1708doi: 10.1172/JCI120803.
Lin, H., Wei, S., Hurt, E. M., Green, M. D., Zhao, L., Vatan, L., Szeliga, W., Herbst, R., Harms, P. W., Fecher, L. A., Vats, P., Chinnaiyan, A. M., Lao, C. D., Lawrence, T. S., Wicha, M., Hamanishi, J., Mandai, M., Kryczek, I., & Zou, W. (2018). Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. The Journal of clinical investigation, 128(4), 1708. https://doi.org/10.1172/JCI120803
Lin, Heng, et al. "Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression." The Journal of clinical investigation vol. 128,4 (2018): 1708. doi: https://doi.org/10.1172/JCI120803
Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest. 2018 Apr 02;128(4):1708. doi: 10.1172/JCI120803. Epub 2018 Apr 02. PMID: 29608143; PMCID: PMC5873851.
Copy Download .nbib Format: NLM
Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy.

Oncotarget

Hovelson DH, Liu CJ, Wang Y, Kang Q, Henderson J, Gursky A, Brockman S, Ramnath N, Krauss JC, Talpaz M, Kandarpa M, Chugh R, Tuck M, Herman K, Grasso CS, Quist MJ, Feng FY, Haakenson C, Langmore J, Kamberov E, Tesmer T, Husain H, Lonigro RJ, Robinson D, Smith DC, Alva AS, Hussain MH, Chinnaiyan AM, Tewari M, Mills RE, Morgan TM, Tomlins SA.
PMID: 29163793
Oncotarget. 2017 Sep 22;8(52):89848-89866. doi: 10.18632/oncotarget.21163. eCollection 2017 Oct 27.

Current cell-free DNA (cfDNA) next generation sequencing (NGS) precision oncology workflows are typically limited to targeted and/or disease-specific applications. In advanced cancer, disease burden and cfDNA tumor content are often elevated, yielding unique precision oncology opportunities. We sought to...

Cite
Hovelson DH, Liu CJ, Wang Y, et al. Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. Oncotarget. 2017;8(52):89848-89866doi: 10.18632/oncotarget.21163.
Hovelson, D. H., Liu, C. J., Wang, Y., Kang, Q., Henderson, J., Gursky, A., Brockman, S., Ramnath, N., Krauss, J. C., Talpaz, M., Kandarpa, M., Chugh, R., Tuck, M., Herman, K., Grasso, C. S., Quist, M. J., Feng, F. Y., Haakenson, C., Langmore, J., Kamberov, E., Tesmer, T., Husain, H., Lonigro, R. J., Robinson, D., Smith, D. C., Alva, A. S., Hussain, M. H., Chinnaiyan, A. M., Tewari, M., Mills, R. E., Morgan, T. M., & Tomlins, S. A. (2017). Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. Oncotarget, 8(52), 89848-89866. https://doi.org/10.18632/oncotarget.21163
Hovelson, Daniel H, et al. "Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy." Oncotarget vol. 8,52 (2017): 89848-89866. doi: https://doi.org/10.18632/oncotarget.21163
Hovelson DH, Liu CJ, Wang Y, Kang Q, Henderson J, Gursky A, Brockman S, Ramnath N, Krauss JC, Talpaz M, Kandarpa M, Chugh R, Tuck M, Herman K, Grasso CS, Quist MJ, Feng FY, Haakenson C, Langmore J, Kamberov E, Tesmer T, Husain H, Lonigro RJ, Robinson D, Smith DC, Alva AS, Hussain MH, Chinnaiyan AM, Tewari M, Mills RE, Morgan TM, Tomlins SA. Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. Oncotarget. 2017 Sep 22;8(52):89848-89866. doi: 10.18632/oncotarget.21163. eCollection 2017 Oct 27. PMID: 29163793; PMCID: PMC5685714.
Copy Download .nbib Format: NLM
Utility of ERG Immunohistochemistry for Evaluation of Lymphovascular Invasion in Testicular Germ Cell Tumors: A Retrospective Pilot Study.

Applied immunohistochemistry & molecular morphology : AIMM

Udager AM, McHugh JB, Morgan TM, Spratt DE, Chinnaiyan AM, Mehra R.
PMID: 28968266
Appl Immunohistochem Mol Morphol. 2019 May/Jun;27(5):392-401. doi: 10.1097/PAI.0000000000000597.

Lymphovascular invasion (LVI) of testicular germ cell tumors (GCT) is an important stage-determining variable in the evaluation of radical orchiectomy specimens. ERG endothelial cell expression, as detected by immunohistochemistry (IHC), robustly highlights lymphovascular spaces, and thus, we sought to...

Cite
Udager AM, McHugh JB, Morgan TM, et al. Utility of ERG Immunohistochemistry for Evaluation of Lymphovascular Invasion in Testicular Germ Cell Tumors: A Retrospective Pilot Study. Appl Immunohistochem Mol Morphol. 2019;27(5):392-401doi: 10.1097/PAI.0000000000000597.
Udager, A. M., McHugh, J. B., Morgan, T. M., Spratt, D. E., Chinnaiyan, A. M., & Mehra, R. (2019). Utility of ERG Immunohistochemistry for Evaluation of Lymphovascular Invasion in Testicular Germ Cell Tumors: A Retrospective Pilot Study. Applied immunohistochemistry & molecular morphology : AIMM, 27(5), 392-401. https://doi.org/10.1097/PAI.0000000000000597
Udager, Aaron M, et al. "Utility of ERG Immunohistochemistry for Evaluation of Lymphovascular Invasion in Testicular Germ Cell Tumors: A Retrospective Pilot Study." Applied immunohistochemistry & molecular morphology : AIMM vol. 27,5 (2019): 392-401. doi: https://doi.org/10.1097/PAI.0000000000000597
Udager AM, McHugh JB, Morgan TM, Spratt DE, Chinnaiyan AM, Mehra R. Utility of ERG Immunohistochemistry for Evaluation of Lymphovascular Invasion in Testicular Germ Cell Tumors: A Retrospective Pilot Study. Appl Immunohistochem Mol Morphol. 2019 May/Jun;27(5):392-401. doi: 10.1097/PAI.0000000000000597. PMID: 28968266; PMCID: PMC5876063.
Copy Download .nbib Format: NLM
Is the HERV-K HML-2 Xq21.33, an endogenous retrovirus mutated by gene conversion of chromosome X in a subset of African populations, associated with human breast cancer?.

Infectious agents and cancer

Kaplan MH, Contreras-Galindo R, Jiagge E, Merajver SD, Newman L, Bigman G, Dosik MH, Palapattu GS, Siddiqui J, Chinnaiyan AM, Adebamowo S, Adebamowo C.
PMID: 32165916
Infect Agent Cancer. 2020 Mar 07;15:19. doi: 10.1186/s13027-020-00284-w. eCollection 2020.

The human endogenous retroviruses HERV-K HML-2 have been considered a possible cause of human breast cancer (BrC). A HERV-K HML-2 fully intact provirus Xq21.33 was recently identified in some West African people. We used PCR technology to search for...

Cite
Kaplan MH, Contreras-Galindo R, Jiagge E, et al. Is the HERV-K HML-2 Xq21.33, an endogenous retrovirus mutated by gene conversion of chromosome X in a subset of African populations, associated with human breast cancer?. Infect Agent Cancer. 2020;15:19doi: 10.1186/s13027-020-00284-w.
Kaplan, M. H., Contreras-Galindo, R., Jiagge, E., Merajver, S. D., Newman, L., Bigman, G., Dosik, M. H., Palapattu, G. S., Siddiqui, J., Chinnaiyan, A. M., Adebamowo, S., & Adebamowo, C. (2020). Is the HERV-K HML-2 Xq21.33, an endogenous retrovirus mutated by gene conversion of chromosome X in a subset of African populations, associated with human breast cancer?. Infectious agents and cancer, 1519. https://doi.org/10.1186/s13027-020-00284-w
Kaplan, Mark H, et al. "Is the HERV-K HML-2 Xq21.33, an endogenous retrovirus mutated by gene conversion of chromosome X in a subset of African populations, associated with human breast cancer?." Infectious agents and cancer vol. 15 (2020): 19. doi: https://doi.org/10.1186/s13027-020-00284-w
Kaplan MH, Contreras-Galindo R, Jiagge E, Merajver SD, Newman L, Bigman G, Dosik MH, Palapattu GS, Siddiqui J, Chinnaiyan AM, Adebamowo S, Adebamowo C. Is the HERV-K HML-2 Xq21.33, an endogenous retrovirus mutated by gene conversion of chromosome X in a subset of African populations, associated with human breast cancer?. Infect Agent Cancer. 2020 Mar 07;15:19. doi: 10.1186/s13027-020-00284-w. eCollection 2020. PMID: 32165916; PMCID: PMC7060579.
Copy Download .nbib Format: NLM
The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.

Clinical cancer research : an official journal of the American Association for Cancer Research

Palanisamy N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, Labanca E, Manyam GC, Ravoori MK, Kundra V, Araujo JC, Efstathiou E, Pisters LL, Wan X, Wang X, Vazquez ES, Aparicio AM, Carskadon SL, Tomlins SA, Kunju LP, Chinnaiyan AM, Broom BM, Logothetis CJ, Troncoso P, Navone NM.
PMID: 32576626
Clin Cancer Res. 2020 Sep 15;26(18):4933-4946. doi: 10.1158/1078-0432.CCR-20-0479. Epub 2020 Jun 23.

PURPOSE: Advances in prostate cancer lag behind other tumor types partly due to the paucity of models reflecting key milestones in prostate cancer progression. Therefore, we develop clinically relevant prostate cancer models.EXPERIMENTAL DESIGN: Since 1996, we have generated clinically...

Cite
Palanisamy N, Yang J, Shepherd PDA, et al. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clin Cancer Res. 2020;26(18):4933-4946doi: 10.1158/1078-0432.CCR-20-0479.
Palanisamy, N., Yang, J., Shepherd, P. D. A., Li-Ning-Tapia, E. M., Labanca, E., Manyam, G. C., Ravoori, M. K., Kundra, V., Araujo, J. C., Efstathiou, E., Pisters, L. L., Wan, X., Wang, X., Vazquez, E. S., Aparicio, A. M., Carskadon, S. L., Tomlins, S. A., Kunju, L. P., Chinnaiyan, A. M., Broom, B. M., Logothetis, C. J., Troncoso, P., & Navone, N. M. (2020). The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(18), 4933-4946. https://doi.org/10.1158/1078-0432.CCR-20-0479
Palanisamy, Nallasivam, et al. "The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 26,18 (2020): 4933-4946. doi: https://doi.org/10.1158/1078-0432.CCR-20-0479
Palanisamy N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, Labanca E, Manyam GC, Ravoori MK, Kundra V, Araujo JC, Efstathiou E, Pisters LL, Wan X, Wang X, Vazquez ES, Aparicio AM, Carskadon SL, Tomlins SA, Kunju LP, Chinnaiyan AM, Broom BM, Logothetis CJ, Troncoso P, Navone NM. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clin Cancer Res. 2020 Sep 15;26(18):4933-4946. doi: 10.1158/1078-0432.CCR-20-0479. Epub 2020 Jun 23. PMID: 32576626; PMCID: PMC7501166.
Copy Download .nbib Format: NLM
Publisher Correction: The long tail of oncogenic drivers in prostate cancer.

Nature genetics

Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM, Schultz N, Van Allen EM.
PMID: 31152158
Nat Genet. 2019 Jul;51(7):1194. doi: 10.1038/s41588-019-0451-6.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Cite
Armenia J, Wankowicz SAM, Liu D, et al. Publisher Correction: The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2019;51(7):1194doi: 10.1038/s41588-019-0451-6.
Armenia, J., Wankowicz, S. A. M., Liu, D., Gao, J., Kundra, R., Reznik, E., Chatila, W. K., Chakravarty, D., Han, G. C., Coleman, I., Montgomery, B., Pritchard, C., Morrissey, C., Barbieri, C. E., Beltran, H., Sboner, A., Zafeiriou, Z., Miranda, S., Bielski, C. M., Penson, A. V., Tolonen, C., Huang, F. W., Robinson, D., Wu, Y. M., Lonigro, R., Garraway, L. A., Demichelis, F., Kantoff, P. W., Taplin, M. E., Abida, W., Taylor, B. S., Scher, H. I., Nelson, P. S., de Bono, J. S., Rubin, M. A., Sawyers, C. L., Chinnaiyan, A. M., Schultz, N., & Van Allen, E. M. (2019). Publisher Correction: The long tail of oncogenic drivers in prostate cancer. Nature genetics, 51(7), 1194. https://doi.org/10.1038/s41588-019-0451-6
Armenia, Joshua, et al. "Publisher Correction: The long tail of oncogenic drivers in prostate cancer." Nature genetics vol. 51,7 (2019): 1194. doi: https://doi.org/10.1038/s41588-019-0451-6
Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM, Schultz N, Van Allen EM. Publisher Correction: The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2019 Jul;51(7):1194. doi: 10.1038/s41588-019-0451-6. PMID: 31152158.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 119 entries